Sartans Art 31 - assessment report
Angiotensin-II-receptor antagonists /blockers (further referred to as “sartans” or “ARBs”) are authorised in the EU as a single agent or in combination with other active substances to be administered orally. They are acting on the AT1 receptor subtype thus blocking the effect of angiotensin-II in the renin-angiotensin-system (RAS) cascade.
Download Sartans Art 31 - assessment report
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Florida Medicaid Preferred Drug List (effective 10-01-2021)
ahca.myflorida.coma4f antihypertensives, angiotensin receptor antagonist irbesartan 150 mg tablet irbesartan 0 999 no page 4 of 145. hic3 hic3 description label name generic name medicaid min age medicaid max age clinical pa required a4f antihypertensives, angiotensin receptor antagonist irbesartan 150 mg tablet irbesartan 0
ANGIOTENSIN RECEPTOR BLOCKER (ARB) COMPARISON …
blessing.orgƗ Product in stock for Blessings International. ANGIOTENSIN RECEPTOR BLOCKER (ARB) COMPARISON CHART ƗLosartan Candesartan Irbesartan Olmesartan Telmisartan Valsartan FDA Indications Hypertension Hypertension with LVH …
Drug Allergy: An Updated Practice Parameter
www.aaaai.orgS. Angiotensin-converting enzyme (ACE) inhibitors T. Biologic modifiers 1. Cytokines 2. Anti–TNF- drugs 3. Monoclonal antibodies 4. Omalizumab 5. Anticancer monoclonal antibodies U. Complementary medicines V. Other agents CONTRIBUTORS The Joint Task Force has made a concerted effort to acknowl-edge all contributors to this parameter. If any ...
JNC 8 Hypertension Guideline Algorithm Initial Drugs of ...
www.umpquahealth.com• Angiotensin receptor blocker (ARB) • Thiazide diuretic • Calcium channel blocker (CCB) At blood pressure goal? Strategy Description A Start one drug, titrate to maximum dose, and then add a second drug. B Start one drug, then add a second drug before achieving max dose of first C Begin 2 drugs at same time, as